Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Oligodeoxyribonucleotides | 130 | 2020 | 243 | 11.140 |
Why?
|
CpG Islands | 94 | 2011 | 212 | 9.460 |
Why?
|
Adjuvants, Immunologic | 90 | 2021 | 228 | 7.980 |
Why?
|
Toll-Like Receptor 9 | 45 | 2021 | 196 | 4.270 |
Why?
|
DNA, Bacterial | 37 | 2010 | 260 | 3.960 |
Why?
|
B-Lymphocytes | 48 | 2007 | 550 | 3.120 |
Why?
|
Oligonucleotides | 28 | 2022 | 208 | 2.650 |
Why?
|
Lymphocyte Activation | 47 | 2013 | 739 | 2.260 |
Why?
|
DNA | 31 | 2009 | 792 | 2.230 |
Why?
|
Oligonucleotides, Antisense | 16 | 2022 | 133 | 2.140 |
Why?
|
Dinucleoside Phosphates | 21 | 2008 | 32 | 2.100 |
Why?
|
Immunity, Innate | 26 | 2017 | 762 | 2.090 |
Why?
|
Receptors, Cell Surface | 20 | 2005 | 439 | 2.000 |
Why?
|
Animals | 194 | 2022 | 19638 | 1.690 |
Why?
|
Mice | 149 | 2020 | 10272 | 1.630 |
Why?
|
Th1 Cells | 25 | 2008 | 172 | 1.550 |
Why?
|
Cytokines | 36 | 2011 | 905 | 1.470 |
Why?
|
Membrane Glycoproteins | 20 | 2012 | 667 | 1.470 |
Why?
|
Dendritic Cells | 29 | 2008 | 508 | 1.380 |
Why?
|
Cancer Vaccines | 17 | 2013 | 48 | 1.340 |
Why?
|
NF-kappa B | 16 | 2006 | 461 | 1.320 |
Why?
|
Lupus Erythematosus, Systemic | 13 | 2007 | 158 | 1.320 |
Why?
|
Autoimmunity | 11 | 2009 | 221 | 1.280 |
Why?
|
Vaccines, DNA | 18 | 2010 | 99 | 1.230 |
Why?
|
Interleukin-12 | 26 | 2008 | 123 | 1.190 |
Why?
|
DNA-Binding Proteins | 18 | 2010 | 1131 | 1.150 |
Why?
|
Thionucleotides | 17 | 2011 | 38 | 1.140 |
Why?
|
Toll-Like Receptor 7 | 11 | 2012 | 96 | 1.080 |
Why?
|
Mice, Inbred BALB C | 48 | 2013 | 879 | 1.070 |
Why?
|
Base Sequence | 44 | 2010 | 1311 | 1.050 |
Why?
|
Antineoplastic Agents | 12 | 2012 | 645 | 1.030 |
Why?
|
Vaccines | 7 | 2009 | 97 | 0.990 |
Why?
|
Interferon-gamma | 36 | 2013 | 538 | 0.990 |
Why?
|
Muscular Dystrophy, Duchenne | 2 | 2016 | 42 | 0.980 |
Why?
|
Toll-Like Receptors | 14 | 2008 | 434 | 0.960 |
Why?
|
Autoimmune Diseases | 12 | 2008 | 222 | 0.900 |
Why?
|
T-Lymphocytes | 27 | 2021 | 964 | 0.840 |
Why?
|
Neoplasms | 13 | 2012 | 1244 | 0.830 |
Why?
|
Interferon-alpha | 17 | 2008 | 98 | 0.810 |
Why?
|
Toll-Like Receptor 8 | 9 | 2010 | 44 | 0.790 |
Why?
|
Signal Transduction | 19 | 2010 | 2886 | 0.770 |
Why?
|
Immunity, Cellular | 12 | 2020 | 176 | 0.760 |
Why?
|
Humans | 126 | 2024 | 59413 | 0.760 |
Why?
|
Lipopolysaccharides | 13 | 2005 | 645 | 0.750 |
Why?
|
Apoptosis | 13 | 2003 | 1038 | 0.750 |
Why?
|
Cells, Cultured | 38 | 2010 | 2099 | 0.740 |
Why?
|
Leukocytes, Mononuclear | 13 | 2008 | 237 | 0.670 |
Why?
|
Morpholinos | 2 | 2016 | 50 | 0.670 |
Why?
|
Mitogen-Activated Protein Kinases | 6 | 2003 | 201 | 0.650 |
Why?
|
Reference Standards | 1 | 2019 | 61 | 0.640 |
Why?
|
Killer Cells, Natural | 17 | 2008 | 214 | 0.640 |
Why?
|
Dystrophin | 2 | 2016 | 35 | 0.620 |
Why?
|
Nucleic Acids | 1 | 2019 | 50 | 0.610 |
Why?
|
DNA, Single-Stranded | 1 | 2019 | 100 | 0.600 |
Why?
|
DNA, Viral | 5 | 2010 | 228 | 0.600 |
Why?
|
Melanoma | 7 | 2024 | 334 | 0.590 |
Why?
|
Exons | 2 | 2016 | 193 | 0.590 |
Why?
|
Chemokines, CXC | 6 | 2007 | 27 | 0.590 |
Why?
|
Lymphoma, B-Cell | 9 | 2007 | 59 | 0.580 |
Why?
|
Autoantigens | 3 | 2007 | 125 | 0.580 |
Why?
|
Vaccination | 10 | 2012 | 338 | 0.570 |
Why?
|
DNA Methylation | 6 | 2001 | 275 | 0.560 |
Why?
|
Mice, Inbred C57BL | 41 | 2015 | 3192 | 0.560 |
Why?
|
Th2 Cells | 9 | 2008 | 98 | 0.550 |
Why?
|
Drug Approval | 1 | 2016 | 27 | 0.540 |
Why?
|
Immunotherapy | 12 | 2009 | 231 | 0.540 |
Why?
|
Cell Division | 13 | 2004 | 442 | 0.530 |
Why?
|
Monocytes | 7 | 2004 | 345 | 0.530 |
Why?
|
Asthma | 7 | 2009 | 420 | 0.520 |
Why?
|
Antibody Formation | 8 | 2007 | 111 | 0.520 |
Why?
|
Communicable Diseases | 4 | 2012 | 82 | 0.500 |
Why?
|
Spleen | 21 | 2006 | 485 | 0.500 |
Why?
|
Retroviridae | 7 | 1994 | 72 | 0.500 |
Why?
|
Immunization | 6 | 2020 | 127 | 0.500 |
Why?
|
Leukocytes | 4 | 2007 | 99 | 0.490 |
Why?
|
Nuclear Proteins | 3 | 2010 | 758 | 0.480 |
Why?
|
Influenza, Human | 1 | 2017 | 193 | 0.480 |
Why?
|
Cell Line | 23 | 2013 | 2012 | 0.480 |
Why?
|
Macrophages | 10 | 2013 | 1004 | 0.480 |
Why?
|
Interleukin-6 | 9 | 2008 | 309 | 0.470 |
Why?
|
Tumor Necrosis Factor-alpha | 14 | 2008 | 580 | 0.460 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 5 | 2024 | 404 | 0.460 |
Why?
|
Mice, Knockout | 21 | 2020 | 1988 | 0.460 |
Why?
|
Muramidase | 4 | 2004 | 47 | 0.460 |
Why?
|
CD8-Positive T-Lymphocytes | 12 | 2013 | 646 | 0.450 |
Why?
|
T-Lymphocytes, Cytotoxic | 9 | 2008 | 165 | 0.440 |
Why?
|
Female | 79 | 2024 | 30879 | 0.430 |
Why?
|
Hypersensitivity | 7 | 2012 | 61 | 0.410 |
Why?
|
Listeriosis | 3 | 2003 | 30 | 0.410 |
Why?
|
Mice, Inbred DBA | 15 | 2002 | 84 | 0.400 |
Why?
|
Molecular Sequence Data | 21 | 1999 | 1973 | 0.380 |
Why?
|
Antiviral Agents | 4 | 2013 | 314 | 0.370 |
Why?
|
Prostatic Neoplasms | 2 | 2006 | 319 | 0.370 |
Why?
|
Antibodies, Anti-Idiotypic | 8 | 2005 | 34 | 0.370 |
Why?
|
Bacterial Vaccines | 3 | 2013 | 90 | 0.370 |
Why?
|
Dose-Response Relationship, Drug | 7 | 2019 | 796 | 0.360 |
Why?
|
Immunity, Active | 3 | 2006 | 10 | 0.350 |
Why?
|
Receptors, Antigen, B-Cell | 5 | 2003 | 58 | 0.350 |
Why?
|
I-kappa B Proteins | 3 | 2001 | 38 | 0.350 |
Why?
|
Tumor Cells, Cultured | 15 | 2006 | 454 | 0.350 |
Why?
|
Transcription Factor AP-1 | 4 | 2003 | 41 | 0.340 |
Why?
|
Genetic Therapy | 4 | 2001 | 734 | 0.340 |
Why?
|
T-Lymphocytes, Regulatory | 3 | 2008 | 196 | 0.340 |
Why?
|
Drug Design | 2 | 2007 | 143 | 0.330 |
Why?
|
Chemokine CXCL10 | 7 | 2007 | 60 | 0.330 |
Why?
|
Flow Cytometry | 11 | 2008 | 638 | 0.330 |
Why?
|
RNA, Small Interfering | 3 | 2012 | 850 | 0.320 |
Why?
|
Paclitaxel | 2 | 2008 | 90 | 0.320 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 6 | 2006 | 72 | 0.320 |
Why?
|
Liver Neoplasms | 3 | 2023 | 276 | 0.320 |
Why?
|
RNA, Viral | 9 | 2009 | 264 | 0.310 |
Why?
|
Hematopoietic Stem Cells | 3 | 1996 | 273 | 0.310 |
Why?
|
Leukemia Virus, Murine | 7 | 1995 | 30 | 0.310 |
Why?
|
Antigens, T-Independent | 2 | 2005 | 10 | 0.300 |
Why?
|
Inflammation | 8 | 2010 | 1097 | 0.300 |
Why?
|
Immune System | 5 | 2010 | 129 | 0.300 |
Why?
|
Cathepsins | 1 | 2008 | 32 | 0.300 |
Why?
|
Bacteremia | 2 | 2006 | 94 | 0.300 |
Why?
|
Receptor for Advanced Glycation End Products | 1 | 2007 | 19 | 0.280 |
Why?
|
Protein-Tyrosine Kinases | 2 | 1998 | 113 | 0.280 |
Why?
|
Autoantibodies | 2 | 2007 | 175 | 0.280 |
Why?
|
Interferon Type I | 7 | 2012 | 167 | 0.280 |
Why?
|
RNA | 6 | 2012 | 403 | 0.280 |
Why?
|
Mice, Inbred C3H | 12 | 2005 | 174 | 0.270 |
Why?
|
Lung | 6 | 2011 | 833 | 0.270 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 12 | 2010 | 448 | 0.270 |
Why?
|
Glanders | 1 | 2006 | 1 | 0.260 |
Why?
|
Burkholderia mallei | 1 | 2006 | 1 | 0.260 |
Why?
|
Antigen Presentation | 8 | 2007 | 228 | 0.260 |
Why?
|
Antigens, CD | 8 | 2011 | 343 | 0.260 |
Why?
|
Chloroquine | 4 | 2003 | 48 | 0.260 |
Why?
|
Neuroblastoma | 2 | 2006 | 85 | 0.260 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 3 | 2003 | 52 | 0.260 |
Why?
|
Germ-Free Life | 1 | 2005 | 8 | 0.260 |
Why?
|
Neoplasm Proteins | 6 | 2008 | 276 | 0.260 |
Why?
|
Prostate-Specific Antigen | 1 | 2006 | 66 | 0.260 |
Why?
|
RNA, Small Nuclear | 1 | 2005 | 25 | 0.260 |
Why?
|
Gene Transfer Techniques | 3 | 2015 | 304 | 0.250 |
Why?
|
Transcription Factors | 5 | 2002 | 1456 | 0.250 |
Why?
|
Colonic Neoplasms | 3 | 2023 | 213 | 0.250 |
Why?
|
Male | 38 | 2024 | 27541 | 0.250 |
Why?
|
Immunoglobulin G | 10 | 2004 | 452 | 0.250 |
Why?
|
Dose-Response Relationship, Immunologic | 9 | 2012 | 49 | 0.240 |
Why?
|
Clinical Trials as Topic | 3 | 2016 | 442 | 0.240 |
Why?
|
Oligodeoxyribonucleotides, Antisense | 2 | 2001 | 16 | 0.240 |
Why?
|
Gene Expression Regulation | 13 | 2006 | 1537 | 0.240 |
Why?
|
Inosine | 1 | 2004 | 3 | 0.240 |
Why?
|
Ribavirin | 1 | 2004 | 24 | 0.230 |
Why?
|
Mink Cell Focus-Inducing Viruses | 5 | 1993 | 5 | 0.230 |
Why?
|
Neoadjuvant Therapy | 1 | 2024 | 70 | 0.230 |
Why?
|
Endosomes | 6 | 2015 | 169 | 0.230 |
Why?
|
Immunoglobulin M | 6 | 2001 | 112 | 0.230 |
Why?
|
Bone Marrow Transplantation | 4 | 2011 | 133 | 0.220 |
Why?
|
Immunity, Mucosal | 4 | 2002 | 46 | 0.220 |
Why?
|
Listeria monocytogenes | 1 | 2003 | 33 | 0.220 |
Why?
|
In Vitro Techniques | 5 | 2019 | 472 | 0.210 |
Why?
|
Cytotoxicity, Immunologic | 4 | 2006 | 142 | 0.210 |
Why?
|
CD4-Positive T-Lymphocytes | 9 | 2013 | 608 | 0.210 |
Why?
|
Bacteria | 2 | 2003 | 275 | 0.210 |
Why?
|
Reactive Oxygen Species | 3 | 2000 | 202 | 0.210 |
Why?
|
Immunotherapy, Active | 1 | 2003 | 4 | 0.210 |
Why?
|
T-Lymphocyte Subsets | 6 | 2006 | 236 | 0.210 |
Why?
|
Melioidosis | 3 | 2011 | 3 | 0.210 |
Why?
|
Antineoplastic Agents, Immunological | 1 | 2023 | 41 | 0.210 |
Why?
|
Drug Synergism | 7 | 2003 | 132 | 0.210 |
Why?
|
Glutathione Disulfide | 1 | 2002 | 2 | 0.210 |
Why?
|
Thymidine | 3 | 2004 | 25 | 0.210 |
Why?
|
Immune Tolerance | 5 | 2009 | 169 | 0.210 |
Why?
|
Hepatitis B Vaccines | 4 | 2005 | 13 | 0.210 |
Why?
|
Radiosurgery | 1 | 2023 | 61 | 0.210 |
Why?
|
Systemic Inflammatory Response Syndrome | 1 | 2003 | 42 | 0.200 |
Why?
|
Poly G | 1 | 2002 | 3 | 0.200 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 3 | 1999 | 98 | 0.200 |
Why?
|
Vaccines, Synthetic | 5 | 2012 | 68 | 0.200 |
Why?
|
Vaccinia virus | 2 | 2017 | 71 | 0.200 |
Why?
|
Antigens, Neoplasm | 7 | 2006 | 135 | 0.200 |
Why?
|
Immunoglobulin A | 2 | 2008 | 93 | 0.200 |
Why?
|
Phosphates | 1 | 2003 | 88 | 0.200 |
Why?
|
Cyclic AMP Response Element-Binding Protein | 2 | 2000 | 44 | 0.200 |
Why?
|
Rectal Neoplasms | 1 | 2023 | 97 | 0.200 |
Why?
|
Transcription, Genetic | 9 | 2003 | 847 | 0.200 |
Why?
|
Imidazoles | 5 | 2010 | 83 | 0.200 |
Why?
|
Time Factors | 10 | 2016 | 3573 | 0.200 |
Why?
|
Malaria Vaccines | 3 | 2012 | 24 | 0.200 |
Why?
|
Glycolates | 1 | 2001 | 2 | 0.200 |
Why?
|
Macrophage Activation | 5 | 2004 | 119 | 0.190 |
Why?
|
Influenza Vaccines | 2 | 2004 | 88 | 0.190 |
Why?
|
Interleukin-10 | 6 | 2004 | 147 | 0.190 |
Why?
|
Transfection | 7 | 2006 | 674 | 0.190 |
Why?
|
Oligoribonucleotides | 3 | 2011 | 14 | 0.190 |
Why?
|
Immunosuppressive Agents | 5 | 2003 | 303 | 0.190 |
Why?
|
Lactoferrin | 1 | 2001 | 40 | 0.190 |
Why?
|
Arthritis, Rheumatoid | 3 | 2002 | 325 | 0.190 |
Why?
|
Streptococcus agalactiae | 1 | 2001 | 80 | 0.190 |
Why?
|
Tularemia | 2 | 2013 | 17 | 0.190 |
Why?
|
Francisella tularensis | 2 | 2013 | 23 | 0.190 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 4 | 2003 | 123 | 0.180 |
Why?
|
Pulmonary Eosinophilia | 1 | 2000 | 7 | 0.180 |
Why?
|
Colorectal Neoplasms | 1 | 2023 | 254 | 0.180 |
Why?
|
Antigens, Bacterial | 3 | 2009 | 214 | 0.170 |
Why?
|
Injections, Subcutaneous | 7 | 2013 | 70 | 0.170 |
Why?
|
Lymphocytes | 3 | 1996 | 193 | 0.170 |
Why?
|
Cell Proliferation | 7 | 2013 | 942 | 0.170 |
Why?
|
Tissue Distribution | 3 | 2015 | 283 | 0.170 |
Why?
|
Vaccines, Virus-Like Particle | 1 | 2020 | 16 | 0.170 |
Why?
|
Adenoviridae | 2 | 2007 | 120 | 0.170 |
Why?
|
Arthritis, Infectious | 1 | 1999 | 18 | 0.170 |
Why?
|
Immunization, Secondary | 1 | 1999 | 46 | 0.170 |
Why?
|
Vertebrates | 1 | 2000 | 41 | 0.170 |
Why?
|
Structure-Activity Relationship | 5 | 2015 | 375 | 0.170 |
Why?
|
Joints | 1 | 1999 | 30 | 0.170 |
Why?
|
ErbB Receptors | 2 | 1997 | 113 | 0.160 |
Why?
|
Bone Marrow | 3 | 1996 | 174 | 0.160 |
Why?
|
Peptides | 5 | 2011 | 545 | 0.160 |
Why?
|
Lymphoma | 1 | 2020 | 99 | 0.160 |
Why?
|
Animals, Newborn | 6 | 2010 | 230 | 0.160 |
Why?
|
Chemokines | 5 | 2007 | 94 | 0.160 |
Why?
|
Plasmodium yoelii | 3 | 2004 | 6 | 0.160 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1998 | 29 | 0.160 |
Why?
|
Programmed Cell Death 1 Receptor | 2 | 2021 | 56 | 0.160 |
Why?
|
Cyclosporine | 1 | 1998 | 57 | 0.150 |
Why?
|
Enhancer Elements, Genetic | 2 | 1998 | 101 | 0.150 |
Why?
|
Histocompatibility Antigens Class II | 7 | 2013 | 179 | 0.150 |
Why?
|
Vaccinia | 1 | 2017 | 31 | 0.150 |
Why?
|
Injections, Intraperitoneal | 5 | 2003 | 45 | 0.150 |
Why?
|
Swine | 3 | 2008 | 344 | 0.150 |
Why?
|
Antigens | 5 | 2010 | 146 | 0.150 |
Why?
|
Viral Vaccines | 1 | 2017 | 49 | 0.140 |
Why?
|
Phosphorylation | 4 | 2003 | 858 | 0.140 |
Why?
|
Neoplasms, Experimental | 3 | 2007 | 74 | 0.140 |
Why?
|
HIV Infections | 4 | 2008 | 920 | 0.140 |
Why?
|
Treatment Outcome | 8 | 2017 | 5172 | 0.140 |
Why?
|
Protein Processing, Post-Translational | 1 | 1998 | 254 | 0.140 |
Why?
|
Walk Test | 1 | 2016 | 7 | 0.140 |
Why?
|
Simian Acquired Immunodeficiency Syndrome | 2 | 2009 | 63 | 0.140 |
Why?
|
Homeodomain Proteins | 1 | 1998 | 254 | 0.140 |
Why?
|
Mice, Inbred Strains | 9 | 2003 | 182 | 0.140 |
Why?
|
Burkholderia pseudomallei | 3 | 2011 | 3 | 0.140 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2007 | 51 | 0.140 |
Why?
|
Membrane Proteins | 3 | 2013 | 841 | 0.130 |
Why?
|
HIV-1 | 4 | 2008 | 705 | 0.130 |
Why?
|
RNA, Messenger | 8 | 2008 | 1469 | 0.130 |
Why?
|
Leukemia | 1 | 1996 | 53 | 0.130 |
Why?
|
Repressor Proteins | 1 | 1998 | 336 | 0.130 |
Why?
|
Cystic Fibrosis | 1 | 1997 | 108 | 0.130 |
Why?
|
Epitopes, T-Lymphocyte | 4 | 2006 | 177 | 0.130 |
Why?
|
Kinetics | 7 | 2004 | 729 | 0.130 |
Why?
|
Peptide Fragments | 4 | 2008 | 349 | 0.130 |
Why?
|
Mitochondria | 1 | 1999 | 336 | 0.130 |
Why?
|
Mannitol | 3 | 2008 | 14 | 0.130 |
Why?
|
Oleic Acids | 3 | 2008 | 6 | 0.130 |
Why?
|
United States Food and Drug Administration | 1 | 2016 | 95 | 0.130 |
Why?
|
Hepatitis B Surface Antigens | 6 | 2005 | 16 | 0.130 |
Why?
|
Malaria | 3 | 2003 | 101 | 0.130 |
Why?
|
Klebsiella Infections | 2 | 2007 | 22 | 0.130 |
Why?
|
Transforming Growth Factor alpha | 1 | 1995 | 16 | 0.130 |
Why?
|
Cattle | 7 | 2008 | 304 | 0.130 |
Why?
|
Enzyme Inhibitors | 4 | 2004 | 341 | 0.130 |
Why?
|
Apolipoprotein C-III | 1 | 2015 | 7 | 0.130 |
Why?
|
Mice, Transgenic | 4 | 2015 | 1223 | 0.130 |
Why?
|
Apolipoproteins B | 1 | 2015 | 19 | 0.130 |
Why?
|
Caco-2 Cells | 1 | 1995 | 65 | 0.130 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 3 | 2002 | 125 | 0.130 |
Why?
|
Adult | 17 | 2024 | 15759 | 0.130 |
Why?
|
Cell Communication | 3 | 2006 | 127 | 0.130 |
Why?
|
Antigen-Presenting Cells | 3 | 2008 | 176 | 0.120 |
Why?
|
Dimerization | 1 | 2015 | 146 | 0.120 |
Why?
|
Cholesterol | 2 | 1995 | 255 | 0.120 |
Why?
|
Recombinant Proteins | 6 | 2012 | 692 | 0.120 |
Why?
|
Polymethacrylic Acids | 1 | 2015 | 10 | 0.120 |
Why?
|
Disease Models, Animal | 10 | 2017 | 2067 | 0.120 |
Why?
|
Pneumonia, Bacterial | 2 | 2007 | 86 | 0.120 |
Why?
|
Escherichia coli | 6 | 2001 | 685 | 0.120 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 1995 | 17 | 0.120 |
Why?
|
Sheep | 4 | 2010 | 166 | 0.120 |
Why?
|
Lipids | 3 | 2013 | 306 | 0.120 |
Why?
|
Genes, env | 2 | 1993 | 15 | 0.120 |
Why?
|
Hydrogen-Ion Concentration | 4 | 2000 | 427 | 0.120 |
Why?
|
Carcinoembryonic Antigen | 2 | 2005 | 32 | 0.120 |
Why?
|
Saccharomyces cerevisiae Proteins | 1 | 1998 | 419 | 0.120 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 4 | 2008 | 525 | 0.110 |
Why?
|
Plasma Cells | 2 | 2005 | 48 | 0.110 |
Why?
|
Polynucleotide 5'-Hydroxyl-Kinase | 1 | 1994 | 2 | 0.110 |
Why?
|
Bacteriophage T4 | 1 | 1994 | 7 | 0.110 |
Why?
|
Endocytosis | 5 | 2015 | 148 | 0.110 |
Why?
|
Encephalitis Virus, Venezuelan Equine | 1 | 2013 | 1 | 0.110 |
Why?
|
Encephalomyelitis, Venezuelan Equine | 1 | 2013 | 1 | 0.110 |
Why?
|
Genetic Vectors | 1 | 2000 | 813 | 0.110 |
Why?
|
Carcinoma, Papillary | 1 | 2013 | 36 | 0.110 |
Why?
|
RNA Splicing | 1 | 2015 | 160 | 0.110 |
Why?
|
Tetanus Toxoid | 2 | 2012 | 14 | 0.110 |
Why?
|
Injections, Intravenous | 3 | 2004 | 148 | 0.110 |
Why?
|
Lymphatic Metastasis | 1 | 2013 | 71 | 0.110 |
Why?
|
Merozoite Surface Protein 1 | 2 | 2004 | 20 | 0.110 |
Why?
|
Deoxycytosine Nucleotides | 2 | 2005 | 4 | 0.110 |
Why?
|
Deoxyguanosine | 2 | 2005 | 20 | 0.110 |
Why?
|
Gene Expression Regulation, Viral | 2 | 1992 | 46 | 0.110 |
Why?
|
Chemoprevention | 1 | 2013 | 38 | 0.110 |
Why?
|
Pore Forming Cytotoxic Proteins | 3 | 2009 | 33 | 0.110 |
Why?
|
Ligands | 4 | 2008 | 420 | 0.110 |
Why?
|
Gene Expression | 3 | 2008 | 807 | 0.110 |
Why?
|
Protein Binding | 4 | 2002 | 1548 | 0.110 |
Why?
|
Thyroid Neoplasms | 1 | 2013 | 77 | 0.110 |
Why?
|
DNA, Antisense | 1 | 1993 | 17 | 0.110 |
Why?
|
Liver | 2 | 2015 | 784 | 0.110 |
Why?
|
Hepatitis B | 2 | 2005 | 28 | 0.110 |
Why?
|
Cytosol | 2 | 2013 | 169 | 0.110 |
Why?
|
Combined Modality Therapy | 3 | 2009 | 354 | 0.110 |
Why?
|
Virus Shedding | 2 | 2010 | 17 | 0.100 |
Why?
|
Macaca mulatta | 5 | 2009 | 247 | 0.100 |
Why?
|
Administration, Inhalation | 2 | 2006 | 110 | 0.100 |
Why?
|
Organophosphorus Compounds | 1 | 1993 | 32 | 0.100 |
Why?
|
Adolescent | 5 | 2016 | 5919 | 0.100 |
Why?
|
Middle Aged | 13 | 2024 | 16246 | 0.100 |
Why?
|
Mutation | 4 | 2015 | 2442 | 0.100 |
Why?
|
Skin Neoplasms | 2 | 2008 | 404 | 0.100 |
Why?
|
Lymph Nodes | 3 | 2007 | 212 | 0.100 |
Why?
|
DNA Primers | 3 | 2004 | 291 | 0.100 |
Why?
|
Bacterial Infections | 2 | 2006 | 138 | 0.100 |
Why?
|
Genes, Viral | 2 | 1989 | 56 | 0.100 |
Why?
|
Cytomegalovirus Vaccines | 1 | 2012 | 5 | 0.100 |
Why?
|
Rats | 4 | 2008 | 1912 | 0.100 |
Why?
|
Antibodies, Monoclonal | 4 | 2010 | 856 | 0.100 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2006 | 162 | 0.100 |
Why?
|
Antigens, Ly | 2 | 2002 | 40 | 0.100 |
Why?
|
Liver Regeneration | 1 | 2011 | 17 | 0.100 |
Why?
|
Species Specificity | 5 | 2006 | 335 | 0.100 |
Why?
|
Down-Regulation | 3 | 2004 | 305 | 0.100 |
Why?
|
Biological Warfare Agents | 1 | 2011 | 2 | 0.100 |
Why?
|
Caspases | 2 | 2003 | 164 | 0.100 |
Why?
|
Cytomegalovirus Infections | 1 | 2012 | 69 | 0.090 |
Why?
|
Immunophenotyping | 4 | 2006 | 185 | 0.090 |
Why?
|
Child | 3 | 2016 | 4304 | 0.090 |
Why?
|
Cell Differentiation | 7 | 2002 | 1293 | 0.090 |
Why?
|
Hepatectomy | 1 | 2011 | 59 | 0.090 |
Why?
|
Aptamers, Nucleotide | 1 | 2011 | 18 | 0.090 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2015 | 672 | 0.090 |
Why?
|
Thymus Gland | 4 | 2001 | 222 | 0.090 |
Why?
|
Carcinoma, Renal Cell | 2 | 2003 | 75 | 0.090 |
Why?
|
Cell Line, Tumor | 6 | 2020 | 1373 | 0.090 |
Why?
|
Aged | 10 | 2024 | 13336 | 0.090 |
Why?
|
Amino Acid Motifs | 3 | 2011 | 153 | 0.090 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 3 | 2024 | 35 | 0.090 |
Why?
|
Drug Carriers | 1 | 1993 | 171 | 0.090 |
Why?
|
Kidney Neoplasms | 2 | 2003 | 114 | 0.090 |
Why?
|
Virus Diseases | 2 | 2006 | 110 | 0.090 |
Why?
|
Parainfluenza Virus 3, Bovine | 1 | 2010 | 1 | 0.090 |
Why?
|
Respirovirus Infections | 1 | 2010 | 6 | 0.090 |
Why?
|
Neoplasm Transplantation | 7 | 2006 | 159 | 0.090 |
Why?
|
NF-KappaB Inhibitor alpha | 3 | 2001 | 26 | 0.090 |
Why?
|
Glycoproteins | 1 | 2011 | 193 | 0.090 |
Why?
|
Retroviridae Infections | 1 | 1990 | 12 | 0.090 |
Why?
|
Biological Therapy | 1 | 2010 | 16 | 0.090 |
Why?
|
Administration, Intranasal | 3 | 2013 | 27 | 0.090 |
Why?
|
Receptors, Pattern Recognition | 1 | 2010 | 31 | 0.090 |
Why?
|
Intercellular Adhesion Molecule-1 | 2 | 2000 | 53 | 0.080 |
Why?
|
Enzyme Activation | 2 | 2002 | 353 | 0.080 |
Why?
|
Specific Pathogen-Free Organisms | 3 | 2001 | 43 | 0.080 |
Why?
|
Cell Cycle | 4 | 2002 | 379 | 0.080 |
Why?
|
HLA-D Antigens | 2 | 2000 | 20 | 0.080 |
Why?
|
Activating Transcription Factor 2 | 2 | 2000 | 10 | 0.080 |
Why?
|
MAP Kinase Signaling System | 2 | 2002 | 201 | 0.080 |
Why?
|
B-Lymphocyte Subsets | 2 | 2003 | 48 | 0.080 |
Why?
|
Antiretroviral Therapy, Highly Active | 2 | 2009 | 94 | 0.080 |
Why?
|
MicroRNAs | 1 | 2015 | 618 | 0.080 |
Why?
|
Spleen Focus-Forming Viruses | 1 | 1989 | 1 | 0.080 |
Why?
|
Virus Inactivation | 1 | 2009 | 2 | 0.080 |
Why?
|
Mice, SCID | 5 | 2008 | 506 | 0.080 |
Why?
|
Protease Inhibitors | 2 | 2008 | 103 | 0.080 |
Why?
|
Plague Vaccine | 1 | 2009 | 5 | 0.080 |
Why?
|
Young Adult | 2 | 2016 | 4317 | 0.080 |
Why?
|
Cytotoxicity Tests, Immunologic | 3 | 2008 | 29 | 0.080 |
Why?
|
SAIDS Vaccines | 1 | 2009 | 23 | 0.080 |
Why?
|
Plague | 1 | 2009 | 23 | 0.080 |
Why?
|
B7-1 Antigen | 3 | 2004 | 73 | 0.080 |
Why?
|
Antibodies, Neoplasm | 2 | 2020 | 27 | 0.080 |
Why?
|
Gene Silencing | 1 | 2011 | 376 | 0.080 |
Why?
|
Nasal Mucosa | 1 | 2008 | 16 | 0.080 |
Why?
|
Biopolymers | 1 | 2009 | 69 | 0.080 |
Why?
|
Histocompatibility Antigens Class I | 3 | 2013 | 130 | 0.080 |
Why?
|
Simian Immunodeficiency Virus | 1 | 2009 | 79 | 0.080 |
Why?
|
Trinitrobenzenes | 2 | 2005 | 7 | 0.080 |
Why?
|
Embolization, Therapeutic | 2 | 2011 | 306 | 0.080 |
Why?
|
Legionella pneumophila | 1 | 2008 | 10 | 0.080 |
Why?
|
Legionnaires' Disease | 1 | 2008 | 8 | 0.080 |
Why?
|
Cathepsin K | 1 | 2008 | 7 | 0.080 |
Why?
|
Lymphoid Tissue | 1 | 2008 | 55 | 0.070 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2008 | 86 | 0.070 |
Why?
|
Bone Marrow Cells | 4 | 2008 | 231 | 0.070 |
Why?
|
Vagina | 2 | 2005 | 82 | 0.070 |
Why?
|
Lipopolysaccharide Receptors | 1 | 2008 | 142 | 0.070 |
Why?
|
Quinolines | 1 | 2008 | 38 | 0.070 |
Why?
|
Host-Pathogen Interactions | 1 | 2010 | 238 | 0.070 |
Why?
|
HIV Antibodies | 1 | 2009 | 141 | 0.070 |
Why?
|
CD3 Complex | 2 | 2010 | 64 | 0.070 |
Why?
|
Macrophages, Alveolar | 1 | 2008 | 59 | 0.070 |
Why?
|
Hemangiosarcoma | 1 | 2007 | 24 | 0.070 |
Why?
|
Genes, myc | 2 | 1998 | 19 | 0.070 |
Why?
|
Klebsiella pneumoniae | 1 | 2007 | 26 | 0.070 |
Why?
|
Virulence | 2 | 2008 | 189 | 0.070 |
Why?
|
Blotting, Northern | 4 | 1991 | 148 | 0.070 |
Why?
|
Blotting, Western | 3 | 2003 | 593 | 0.070 |
Why?
|
Lysosomes | 1 | 2008 | 162 | 0.070 |
Why?
|
Neutrophils | 2 | 2001 | 352 | 0.070 |
Why?
|
Sequence Analysis, RNA | 1 | 2008 | 152 | 0.070 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2008 | 139 | 0.070 |
Why?
|
HMGB1 Protein | 1 | 2006 | 25 | 0.070 |
Why?
|
Receptors, Interferon | 2 | 2004 | 19 | 0.070 |
Why?
|
Endoplasmic Reticulum | 1 | 2008 | 167 | 0.070 |
Why?
|
Respiratory Mucosa | 1 | 2006 | 52 | 0.070 |
Why?
|
Myeloid Progenitor Cells | 1 | 2006 | 12 | 0.070 |
Why?
|
Vaccines, Subunit | 3 | 2017 | 40 | 0.070 |
Why?
|
Receptor, Interferon alpha-beta | 2 | 2004 | 45 | 0.070 |
Why?
|
Drosophila Proteins | 2 | 2002 | 682 | 0.070 |
Why?
|
Herpesvirus 1, Bovine | 1 | 2006 | 1 | 0.070 |
Why?
|
Sheep Diseases | 1 | 2006 | 4 | 0.070 |
Why?
|
CD40 Antigens | 3 | 2001 | 60 | 0.070 |
Why?
|
Viral Envelope Proteins | 2 | 2002 | 107 | 0.060 |
Why?
|
Acetylmuramyl-Alanyl-Isoglutamine | 1 | 2005 | 10 | 0.060 |
Why?
|
Nanoparticles | 1 | 2012 | 498 | 0.060 |
Why?
|
Herpesviridae Infections | 1 | 2006 | 28 | 0.060 |
Why?
|
Aminoquinolines | 1 | 2005 | 15 | 0.060 |
Why?
|
Receptors, IgG | 1 | 2005 | 36 | 0.060 |
Why?
|
Antibodies, Antinuclear | 1 | 2005 | 36 | 0.060 |
Why?
|
Up-Regulation | 5 | 2007 | 363 | 0.060 |
Why?
|
Hemocyanins | 3 | 2005 | 23 | 0.060 |
Why?
|
Plasmids | 2 | 2008 | 282 | 0.060 |
Why?
|
Plasmodium falciparum | 2 | 2004 | 132 | 0.060 |
Why?
|
Fetus | 1 | 2005 | 97 | 0.060 |
Why?
|
Receptors, Antigen, T-Cell, gamma-delta | 2 | 2004 | 54 | 0.060 |
Why?
|
Interleukin-4 | 4 | 2002 | 138 | 0.060 |
Why?
|
Poxviridae Infections | 1 | 2005 | 1 | 0.060 |
Why?
|
Administration, Oral | 2 | 2003 | 344 | 0.060 |
Why?
|
Lung Diseases, Fungal | 1 | 2005 | 31 | 0.060 |
Why?
|
CD40 Ligand | 2 | 2002 | 155 | 0.060 |
Why?
|
Topotecan | 2 | 2003 | 5 | 0.060 |
Why?
|
Sarcoma, Experimental | 1 | 2004 | 6 | 0.060 |
Why?
|
Myeloid Differentiation Factor 88 | 3 | 2012 | 207 | 0.060 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2004 | 14 | 0.060 |
Why?
|
Receptors, Interleukin-2 | 1 | 2004 | 70 | 0.060 |
Why?
|
Interferon-beta | 2 | 2001 | 76 | 0.060 |
Why?
|
Heterocyclic Compounds | 1 | 2004 | 12 | 0.060 |
Why?
|
Immunotherapy, Adoptive | 2 | 2002 | 87 | 0.060 |
Why?
|
Receptors, Tumor Necrosis Factor | 2 | 2003 | 61 | 0.060 |
Why?
|
Interferons | 1 | 2004 | 63 | 0.060 |
Why?
|
Lymphocyte Culture Test, Mixed | 2 | 2004 | 32 | 0.060 |
Why?
|
Rheumatoid Factor | 1 | 2004 | 13 | 0.060 |
Why?
|
Protein Synthesis Inhibitors | 3 | 1999 | 25 | 0.060 |
Why?
|
Cryptococcosis | 1 | 2005 | 71 | 0.060 |
Why?
|
Antigen-Antibody Complex | 1 | 2004 | 49 | 0.060 |
Why?
|
Gastrointestinal Tract | 1 | 2005 | 170 | 0.060 |
Why?
|
Rhabdomyosarcoma, Embryonal | 1 | 2003 | 4 | 0.060 |
Why?
|
Tumor Microenvironment | 1 | 2024 | 143 | 0.060 |
Why?
|
Ipilimumab | 1 | 2023 | 10 | 0.060 |
Why?
|
C-Reactive Protein | 1 | 2004 | 167 | 0.060 |
Why?
|
United States | 1 | 2016 | 7516 | 0.060 |
Why?
|
Microsatellite Repeats | 1 | 2023 | 37 | 0.050 |
Why?
|
Cell Culture Techniques | 2 | 2002 | 178 | 0.050 |
Why?
|
Double-Blind Method | 4 | 2007 | 669 | 0.050 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2003 | 7 | 0.050 |
Why?
|
Subcellular Fractions | 1 | 2003 | 66 | 0.050 |
Why?
|
Animals, Genetically Modified | 1 | 2004 | 281 | 0.050 |
Why?
|
Skin | 3 | 2007 | 353 | 0.050 |
Why?
|
Immune Sera | 1 | 2003 | 35 | 0.050 |
Why?
|
Cryptococcus neoformans | 1 | 2005 | 141 | 0.050 |
Why?
|
Molecular Structure | 1 | 2004 | 376 | 0.050 |
Why?
|
Models, Animal | 1 | 2004 | 221 | 0.050 |
Why?
|
Mice, Inbred A | 1 | 2003 | 20 | 0.050 |
Why?
|
Bacterial Proteins | 1 | 2009 | 749 | 0.050 |
Why?
|
Cell Movement | 4 | 2007 | 422 | 0.050 |
Why?
|
Stereoisomerism | 1 | 2003 | 67 | 0.050 |
Why?
|
Proto-Oncogenes | 2 | 1999 | 8 | 0.050 |
Why?
|
Carmustine | 1 | 2002 | 10 | 0.050 |
Why?
|
Malaria, Falciparum | 1 | 2004 | 115 | 0.050 |
Why?
|
Cell Separation | 1 | 2003 | 147 | 0.050 |
Why?
|
I-kappa B Kinase | 1 | 2003 | 48 | 0.050 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2003 | 74 | 0.050 |
Why?
|
Phenotype | 3 | 2008 | 1150 | 0.050 |
Why?
|
Mice, Inbred NZB | 2 | 1994 | 19 | 0.050 |
Why?
|
Herpesvirus Vaccines | 1 | 2002 | 1 | 0.050 |
Why?
|
Lung Neoplasms | 1 | 2008 | 554 | 0.050 |
Why?
|
Leukemia, Myeloid | 1 | 2002 | 31 | 0.050 |
Why?
|
Models, Biological | 1 | 2008 | 1142 | 0.050 |
Why?
|
Glutathione | 1 | 2002 | 51 | 0.050 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2022 | 96 | 0.050 |
Why?
|
Lymphokines | 1 | 2002 | 66 | 0.050 |
Why?
|
Electrophoretic Mobility Shift Assay | 1 | 2002 | 64 | 0.050 |
Why?
|
Methylation | 2 | 2009 | 126 | 0.050 |
Why?
|
Binding Sites | 3 | 2001 | 871 | 0.050 |
Why?
|
Florida | 1 | 2002 | 40 | 0.050 |
Why?
|
Infant, Newborn | 3 | 2001 | 1306 | 0.050 |
Why?
|
Herpes Simplex | 1 | 2002 | 46 | 0.050 |
Why?
|
Veterinary Medicine | 1 | 2001 | 3 | 0.050 |
Why?
|
Absorbable Implants | 1 | 2001 | 7 | 0.050 |
Why?
|
Mice, Inbred ICR | 1 | 2001 | 27 | 0.050 |
Why?
|
Survival Analysis | 2 | 2013 | 553 | 0.050 |
Why?
|
Animals, Laboratory | 1 | 2001 | 6 | 0.050 |
Why?
|
Phagocytosis | 2 | 2003 | 252 | 0.050 |
Why?
|
Polyglycolic Acid | 1 | 2001 | 16 | 0.050 |
Why?
|
Bronchial Hyperreactivity | 2 | 1999 | 29 | 0.050 |
Why?
|
Uridine | 2 | 2011 | 16 | 0.050 |
Why?
|
Oligonucleotide Probes | 3 | 1990 | 43 | 0.050 |
Why?
|
Microspheres | 1 | 2001 | 55 | 0.050 |
Why?
|
Corticosterone | 1 | 2001 | 22 | 0.050 |
Why?
|
Herpesvirus 1, Human | 1 | 2002 | 73 | 0.050 |
Why?
|
Prostaglandin-Endoperoxide Synthases | 1 | 2001 | 32 | 0.050 |
Why?
|
Prostaglandins | 1 | 2001 | 18 | 0.050 |
Why?
|
Ovalbumin | 3 | 2008 | 114 | 0.050 |
Why?
|
Kidney | 1 | 2004 | 393 | 0.050 |
Why?
|
Pharmaceutical Preparations | 1 | 2022 | 122 | 0.050 |
Why?
|
Risk Factors | 3 | 2013 | 5011 | 0.050 |
Why?
|
Lactic Acid | 1 | 2001 | 70 | 0.050 |
Why?
|
Alcohol Drinking | 1 | 2004 | 299 | 0.050 |
Why?
|
Quality Control | 2 | 2005 | 69 | 0.050 |
Why?
|
CD4 Lymphocyte Count | 3 | 2007 | 92 | 0.050 |
Why?
|
Luciferases | 2 | 2015 | 109 | 0.050 |
Why?
|
Isoenzymes | 1 | 2001 | 132 | 0.050 |
Why?
|
Ficoll | 1 | 2001 | 4 | 0.050 |
Why?
|
Gastrointestinal Microbiome | 1 | 2024 | 195 | 0.050 |
Why?
|
Immunity | 1 | 2002 | 96 | 0.050 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2003 | 324 | 0.050 |
Why?
|
Ethanol | 1 | 2004 | 307 | 0.040 |
Why?
|
Antigens, Surface | 2 | 1993 | 191 | 0.040 |
Why?
|
Polymerase Chain Reaction | 2 | 2003 | 498 | 0.040 |
Why?
|
Ape Diseases | 1 | 2000 | 1 | 0.040 |
Why?
|
Fluorescein-5-isothiocyanate | 2 | 2003 | 20 | 0.040 |
Why?
|
Freund's Adjuvant | 2 | 2013 | 13 | 0.040 |
Why?
|
Polysaccharides | 1 | 2001 | 144 | 0.040 |
Why?
|
Drug Antagonism | 1 | 2000 | 9 | 0.040 |
Why?
|
Pan troglodytes | 1 | 2000 | 35 | 0.040 |
Why?
|
Macaca fascicularis | 1 | 2000 | 47 | 0.040 |
Why?
|
Brucella abortus | 1 | 1999 | 5 | 0.040 |
Why?
|
bcl-X Protein | 1 | 1999 | 19 | 0.040 |
Why?
|
Injections, Intramuscular | 1 | 2000 | 69 | 0.040 |
Why?
|
Cell Survival | 2 | 2015 | 557 | 0.040 |
Why?
|
Concanavalin A | 2 | 1990 | 40 | 0.040 |
Why?
|
Pregnancy | 2 | 2005 | 2354 | 0.040 |
Why?
|
Coculture Techniques | 3 | 2006 | 93 | 0.040 |
Why?
|
Genes, MHC Class II | 1 | 1999 | 36 | 0.040 |
Why?
|
Antimalarials | 1 | 2000 | 68 | 0.040 |
Why?
|
Membrane Potentials | 1 | 1999 | 136 | 0.040 |
Why?
|
Leishmaniasis | 1 | 1999 | 10 | 0.040 |
Why?
|
Solubility | 3 | 2006 | 174 | 0.040 |
Why?
|
Macrophages, Peritoneal | 1 | 1999 | 73 | 0.040 |
Why?
|
Hepatitis B Antibodies | 1 | 1998 | 8 | 0.040 |
Why?
|
2',5'-Oligoadenylate Synthetase | 2 | 2010 | 4 | 0.040 |
Why?
|
Drug Administration Schedule | 3 | 2007 | 279 | 0.040 |
Why?
|
MAP Kinase Kinase 2 | 1 | 1998 | 5 | 0.040 |
Why?
|
Infusions, Intravenous | 2 | 2011 | 169 | 0.040 |
Why?
|
Protozoan Proteins | 1 | 1999 | 80 | 0.040 |
Why?
|
Enzyme Induction | 1 | 1998 | 44 | 0.040 |
Why?
|
Replication Protein C | 1 | 1998 | 6 | 0.040 |
Why?
|
Whole-Body Irradiation | 2 | 2004 | 31 | 0.040 |
Why?
|
Nucleic Acid Conformation | 1 | 2000 | 231 | 0.040 |
Why?
|
Minor Histocompatibility Antigens | 1 | 1998 | 34 | 0.040 |
Why?
|
Flavonoids | 1 | 1998 | 73 | 0.040 |
Why?
|
Transcription Factor RelB | 1 | 1998 | 5 | 0.040 |
Why?
|
Safety | 1 | 1999 | 141 | 0.040 |
Why?
|
B7-2 Antigen | 3 | 2004 | 32 | 0.040 |
Why?
|
Cyclophosphamide | 2 | 2003 | 71 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-rel | 1 | 1998 | 15 | 0.040 |
Why?
|
Pyridines | 1 | 1998 | 98 | 0.040 |
Why?
|
Guanosine | 2 | 2006 | 10 | 0.040 |
Why?
|
Sphingomyelins | 1 | 1997 | 3 | 0.040 |
Why?
|
Okadaic Acid | 1 | 1997 | 9 | 0.040 |
Why?
|
Thapsigargin | 1 | 1997 | 17 | 0.040 |
Why?
|
Immunoglobulin E | 1 | 1998 | 85 | 0.040 |
Why?
|
Monokines | 1 | 1997 | 4 | 0.040 |
Why?
|
Chemokine CXCL2 | 1 | 1997 | 14 | 0.040 |
Why?
|
DNA Fragmentation | 1 | 1997 | 35 | 0.040 |
Why?
|
Carrier State | 1 | 1997 | 18 | 0.040 |
Why?
|
Vitamin K | 1 | 1997 | 17 | 0.040 |
Why?
|
Chemotactic Factors | 1 | 1997 | 26 | 0.040 |
Why?
|
Sputum | 1 | 1997 | 36 | 0.040 |
Why?
|
Least-Squares Analysis | 1 | 1997 | 24 | 0.040 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 1997 | 97 | 0.040 |
Why?
|
Prospective Studies | 1 | 2024 | 3095 | 0.040 |
Why?
|
Nonlinear Dynamics | 1 | 1997 | 24 | 0.040 |
Why?
|
Viral Load | 2 | 2009 | 229 | 0.040 |
Why?
|
Protein Subunits | 1 | 2017 | 164 | 0.040 |
Why?
|
Pseudomonas Infections | 1 | 1997 | 50 | 0.030 |
Why?
|
Genes, bcl-2 | 1 | 1996 | 9 | 0.030 |
Why?
|
Virus Replication | 2 | 2005 | 302 | 0.030 |
Why?
|
Protein Kinase C | 1 | 1997 | 98 | 0.030 |
Why?
|
Conserved Sequence | 1 | 1997 | 171 | 0.030 |
Why?
|
HL-60 Cells | 1 | 1996 | 25 | 0.030 |
Why?
|
Lymphocyte Subsets | 1 | 1996 | 35 | 0.030 |
Why?
|
Pseudomonas aeruginosa | 1 | 1997 | 98 | 0.030 |
Why?
|
Escherichia coli Proteins | 1 | 1999 | 260 | 0.030 |
Why?
|
Amino Acid Sequence | 3 | 2012 | 1576 | 0.030 |
Why?
|
Mice, Nude | 1 | 1996 | 260 | 0.030 |
Why?
|
Proto-Oncogene Proteins | 1 | 1998 | 315 | 0.030 |
Why?
|
Murine Acquired Immunodeficiency Syndrome | 2 | 1995 | 8 | 0.030 |
Why?
|
MART-1 Antigen | 2 | 2006 | 8 | 0.030 |
Why?
|
Heparitin Sulfate | 1 | 2015 | 10 | 0.030 |
Why?
|
Antibodies | 1 | 1996 | 176 | 0.030 |
Why?
|
Epitopes | 2 | 2012 | 295 | 0.030 |
Why?
|
Recurrence | 2 | 2007 | 576 | 0.030 |
Why?
|
Hemolysis | 1 | 2015 | 38 | 0.030 |
Why?
|
Aminoethylphosphonic Acid | 1 | 1994 | 1 | 0.030 |
Why?
|
Polydeoxyribonucleotides | 1 | 1994 | 1 | 0.030 |
Why?
|
Rats, Sprague-Dawley | 2 | 2008 | 569 | 0.030 |
Why?
|
Cyclooxygenase 2 | 2 | 2008 | 76 | 0.030 |
Why?
|
Transplantation, Homologous | 2 | 2008 | 233 | 0.030 |
Why?
|
Antioxidants | 1 | 1996 | 244 | 0.030 |
Why?
|
Mice, Mutant Strains | 2 | 1995 | 304 | 0.030 |
Why?
|
Nitric Oxide | 2 | 2008 | 144 | 0.030 |
Why?
|
Perforin | 2 | 2006 | 29 | 0.030 |
Why?
|
Sequence Analysis, DNA | 1 | 1996 | 397 | 0.030 |
Why?
|
Antibodies, Bacterial | 2 | 2009 | 193 | 0.030 |
Why?
|
Erythrocytes | 1 | 2015 | 154 | 0.030 |
Why?
|
Genes, Reporter | 2 | 2006 | 243 | 0.030 |
Why?
|
Hepatitis A Virus Cellular Receptor 2 | 1 | 2013 | 15 | 0.030 |
Why?
|
T-Cell Antigen Receptor Specificity | 1 | 2013 | 10 | 0.030 |
Why?
|
Iodine Radioisotopes | 1 | 2013 | 51 | 0.030 |
Why?
|
Aged, 80 and over | 3 | 2008 | 5094 | 0.030 |
Why?
|
Thyroidectomy | 1 | 2013 | 32 | 0.030 |
Why?
|
Follow-Up Studies | 2 | 2011 | 2327 | 0.030 |
Why?
|
Lymph Node Excision | 1 | 2013 | 36 | 0.030 |
Why?
|
Biopsy, Fine-Needle | 1 | 2013 | 63 | 0.030 |
Why?
|
HeLa Cells | 1 | 2015 | 526 | 0.030 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2013 | 53 | 0.030 |
Why?
|
HLA-A2 Antigen | 2 | 2005 | 65 | 0.030 |
Why?
|
Temperature | 1 | 1994 | 299 | 0.030 |
Why?
|
Nucleic Acid Hybridization | 2 | 1994 | 104 | 0.030 |
Why?
|
Receptors, LDL | 1 | 1993 | 33 | 0.030 |
Why?
|
Lipoproteins, LDL | 1 | 1993 | 46 | 0.030 |
Why?
|
Organophosphates | 1 | 1993 | 16 | 0.030 |
Why?
|
Molecular Probes | 1 | 1992 | 29 | 0.030 |
Why?
|
Biological Transport, Active | 2 | 2003 | 39 | 0.030 |
Why?
|
Eosinophilia | 2 | 2005 | 28 | 0.030 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 2 | 2004 | 106 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 2 | 2011 | 1464 | 0.030 |
Why?
|
TNF-Related Apoptosis-Inducing Ligand | 2 | 2003 | 11 | 0.030 |
Why?
|
Zidovudine | 1 | 1992 | 12 | 0.020 |
Why?
|
Sjogren's Syndrome | 1 | 1992 | 26 | 0.020 |
Why?
|
AC133 Antigen | 1 | 2011 | 5 | 0.020 |
Why?
|
Lectins, C-Type | 2 | 2004 | 82 | 0.020 |
Why?
|
Bilirubin | 1 | 2011 | 14 | 0.020 |
Why?
|
Aspartate Aminotransferases | 1 | 2011 | 29 | 0.020 |
Why?
|
International Normalized Ratio | 1 | 2011 | 34 | 0.020 |
Why?
|
Liver Failure | 1 | 2011 | 16 | 0.020 |
Why?
|
Antibodies, Protozoan | 2 | 2004 | 45 | 0.020 |
Why?
|
Tumor Burden | 1 | 2011 | 62 | 0.020 |
Why?
|
Portal Vein | 1 | 2011 | 37 | 0.020 |
Why?
|
Blood Buffy Coat | 1 | 2011 | 1 | 0.020 |
Why?
|
Organ Size | 1 | 2011 | 161 | 0.020 |
Why?
|
Phosphorothioate Oligonucleotides | 1 | 2011 | 10 | 0.020 |
Why?
|
Microscopy, Fluorescence | 2 | 2003 | 396 | 0.020 |
Why?
|
Apoptosis Regulatory Proteins | 2 | 2003 | 148 | 0.020 |
Why?
|
Radiation Chimera | 1 | 1991 | 57 | 0.020 |
Why?
|
Immunoglobulins | 2 | 2006 | 76 | 0.020 |
Why?
|
Clone Cells | 2 | 2006 | 106 | 0.020 |
Why?
|
Chromosome Mapping | 1 | 1992 | 293 | 0.020 |
Why?
|
CD8 Antigens | 1 | 1991 | 53 | 0.020 |
Why?
|
Sex Factors | 1 | 2013 | 960 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 2 | 2003 | 501 | 0.020 |
Why?
|
Enterotoxins | 2 | 2001 | 21 | 0.020 |
Why?
|
Thyroiditis, Autoimmune | 1 | 1990 | 8 | 0.020 |
Why?
|
Receptor Cross-Talk | 1 | 2010 | 10 | 0.020 |
Why?
|
Lipopeptides | 1 | 2010 | 17 | 0.020 |
Why?
|
Mice, Inbred CBA | 2 | 2000 | 82 | 0.020 |
Why?
|
CD4 Antigens | 1 | 1991 | 156 | 0.020 |
Why?
|
Chromatography, Gel | 1 | 2010 | 65 | 0.020 |
Why?
|
Trachea | 1 | 2010 | 92 | 0.020 |
Why?
|
Biological Transport | 1 | 1991 | 287 | 0.020 |
Why?
|
Protein Biosynthesis | 1 | 1992 | 293 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2003 | 299 | 0.020 |
Why?
|
Rats, Inbred Lew | 1 | 1989 | 110 | 0.020 |
Why?
|
Immunologic Memory | 2 | 2002 | 276 | 0.020 |
Why?
|
Cell Adhesion | 1 | 2010 | 209 | 0.020 |
Why?
|
Age Factors | 1 | 2013 | 1516 | 0.020 |
Why?
|
Adaptive Immunity | 1 | 2010 | 87 | 0.020 |
Why?
|
Prognosis | 1 | 2013 | 1572 | 0.020 |
Why?
|
2,2'-Dipyridyl | 1 | 2009 | 2 | 0.020 |
Why?
|
Genes, Regulator | 1 | 1989 | 27 | 0.020 |
Why?
|
Viral Proteins | 1 | 1991 | 260 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 1 | 1990 | 192 | 0.020 |
Why?
|
Disinfectants | 1 | 2009 | 20 | 0.020 |
Why?
|
Yersinia pestis | 1 | 2009 | 33 | 0.020 |
Why?
|
Disulfides | 1 | 2009 | 62 | 0.020 |
Why?
|
Taxoids | 1 | 2008 | 26 | 0.020 |
Why?
|
Carboplatin | 1 | 2008 | 40 | 0.020 |
Why?
|
Nasopharynx | 1 | 2008 | 21 | 0.020 |
Why?
|
Toll-Like Receptor 2 | 1 | 2009 | 220 | 0.020 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2010 | 279 | 0.020 |
Why?
|
DNA, Complementary | 1 | 2008 | 166 | 0.020 |
Why?
|
Cisplatin | 1 | 2008 | 119 | 0.020 |
Why?
|
Retrospective Studies | 1 | 1999 | 6000 | 0.020 |
Why?
|
Antigens, CD20 | 1 | 2007 | 14 | 0.020 |
Why?
|
Emergency Treatment | 1 | 2007 | 51 | 0.020 |
Why?
|
Anti-HIV Agents | 1 | 2009 | 154 | 0.020 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2007 | 60 | 0.020 |
Why?
|
Graft vs Host Disease | 1 | 2008 | 99 | 0.020 |
Why?
|
Carrier Proteins | 2 | 2003 | 709 | 0.020 |
Why?
|
Rituximab | 1 | 2007 | 82 | 0.020 |
Why?
|
Adoptive Transfer | 1 | 2007 | 145 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2008 | 576 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2008 | 454 | 0.020 |
Why?
|
Leukocyte Count | 1 | 2007 | 94 | 0.020 |
Why?
|
Body Temperature | 1 | 2006 | 43 | 0.020 |
Why?
|
DNA Viruses | 1 | 2006 | 15 | 0.020 |
Why?
|
Cell-Free System | 1 | 2006 | 31 | 0.020 |
Why?
|
Haptoglobins | 1 | 2006 | 15 | 0.020 |
Why?
|
Bystander Effect | 1 | 2006 | 5 | 0.020 |
Why?
|
Guanine | 1 | 2006 | 22 | 0.020 |
Why?
|
Lymphocyte Count | 1 | 2006 | 70 | 0.020 |
Why?
|
Cell Nucleus | 1 | 1990 | 603 | 0.020 |
Why?
|
Transplantation, Autologous | 1 | 2006 | 118 | 0.020 |
Why?
|
Models, Immunological | 1 | 2006 | 79 | 0.020 |
Why?
|
Reference Values | 1 | 2007 | 319 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2006 | 196 | 0.020 |
Why?
|
Administration, Intravaginal | 1 | 2005 | 11 | 0.020 |
Why?
|
Cytomegalovirus | 1 | 2006 | 88 | 0.020 |
Why?
|
Intubation, Intratracheal | 1 | 2007 | 189 | 0.020 |
Why?
|
Saponins | 1 | 2005 | 28 | 0.020 |
Why?
|
Interferon Regulatory Factor-7 | 1 | 2005 | 33 | 0.020 |
Why?
|
Pilot Projects | 1 | 2008 | 922 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2011 | 1133 | 0.020 |
Why?
|
Fibrosarcoma | 1 | 2005 | 13 | 0.020 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2005 | 54 | 0.020 |
Why?
|
Herpesvirus 4, Human | 1 | 2006 | 181 | 0.010 |
Why?
|
Methylcholanthrene | 1 | 2004 | 2 | 0.010 |
Why?
|
Hemagglutinins | 1 | 2004 | 17 | 0.010 |
Why?
|
Colony Count, Microbial | 1 | 2004 | 57 | 0.010 |
Why?
|
Interphase | 1 | 2004 | 66 | 0.010 |
Why?
|
Cell Fractionation | 1 | 2004 | 31 | 0.010 |
Why?
|
Immunologic Factors | 1 | 2005 | 99 | 0.010 |
Why?
|
Cytoskeletal Proteins | 1 | 2005 | 196 | 0.010 |
Why?
|
Self Administration | 1 | 2004 | 47 | 0.010 |
Why?
|
Forkhead Transcription Factors | 1 | 2004 | 118 | 0.010 |
Why?
|
Aging | 2 | 2001 | 723 | 0.010 |
Why?
|
Antigens, Differentiation | 1 | 2004 | 141 | 0.010 |
Why?
|
Necrosis | 1 | 2004 | 138 | 0.010 |
Why?
|
Macrolides | 1 | 2004 | 38 | 0.010 |
Why?
|
Culture Media | 1 | 2004 | 77 | 0.010 |
Why?
|
BH3 Interacting Domain Death Agonist Protein | 1 | 2003 | 8 | 0.010 |
Why?
|
CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2003 | 9 | 0.010 |
Why?
|
Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2003 | 7 | 0.010 |
Why?
|
X-Linked Inhibitor of Apoptosis Protein | 1 | 2003 | 8 | 0.010 |
Why?
|
Gamma Rays | 1 | 2003 | 31 | 0.010 |
Why?
|
Radiation Dosage | 1 | 2004 | 125 | 0.010 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2003 | 31 | 0.010 |
Why?
|
Nucleic Acid Synthesis Inhibitors | 1 | 2003 | 12 | 0.010 |
Why?
|
Cytochalasin D | 1 | 2003 | 19 | 0.010 |
Why?
|
Biomarkers, Tumor | 1 | 2006 | 453 | 0.010 |
Why?
|
Receptors, Immunologic | 1 | 2004 | 177 | 0.010 |
Why?
|
Giant Cells | 1 | 2003 | 17 | 0.010 |
Why?
|
Caspase 9 | 1 | 2003 | 22 | 0.010 |
Why?
|
Cell Count | 1 | 2003 | 129 | 0.010 |
Why?
|
Caspase 8 | 1 | 2003 | 61 | 0.010 |
Why?
|
Cell Cycle Proteins | 1 | 2005 | 376 | 0.010 |
Why?
|
Oils | 1 | 2003 | 70 | 0.010 |
Why?
|
Models, Molecular | 1 | 2006 | 1124 | 0.010 |
Why?
|
Antibodies, Viral | 1 | 2004 | 305 | 0.010 |
Why?
|
Immunodominant Epitopes | 1 | 2002 | 57 | 0.010 |
Why?
|
Receptors, CCR7 | 1 | 2001 | 6 | 0.010 |
Why?
|
Lymphoma, T-Cell | 1 | 2001 | 21 | 0.010 |
Why?
|
Toll-Like Receptor 1 | 1 | 2001 | 22 | 0.010 |
Why?
|
Piroxicam | 1 | 2001 | 3 | 0.010 |
Why?
|
Gliotoxin | 1 | 2001 | 4 | 0.010 |
Why?
|
Receptors, Chemokine | 1 | 2001 | 32 | 0.010 |
Why?
|
Depression, Chemical | 1 | 2001 | 11 | 0.010 |
Why?
|
Lymphocyte Transfusion | 1 | 2001 | 37 | 0.010 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2001 | 36 | 0.010 |
Why?
|
Lymphocyte Depletion | 1 | 2001 | 95 | 0.010 |
Why?
|
Melanoma, Experimental | 1 | 2001 | 42 | 0.010 |
Why?
|
Cohort Studies | 1 | 2007 | 2443 | 0.010 |
Why?
|
Dinoprostone | 1 | 2001 | 46 | 0.010 |
Why?
|
Restraint, Physical | 1 | 2001 | 31 | 0.010 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 2001 | 42 | 0.010 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2004 | 416 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2003 | 847 | 0.010 |
Why?
|
Biomarkers | 1 | 2006 | 1195 | 0.010 |
Why?
|
Haptens | 1 | 2001 | 13 | 0.010 |
Why?
|
Multienzyme Complexes | 1 | 2001 | 77 | 0.010 |
Why?
|
Staining and Labeling | 1 | 2002 | 124 | 0.010 |
Why?
|
Cysteine Endopeptidases | 1 | 2001 | 90 | 0.010 |
Why?
|
Pneumococcal Vaccines | 1 | 2001 | 19 | 0.010 |
Why?
|
Active Transport, Cell Nucleus | 1 | 2001 | 106 | 0.010 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2001 | 124 | 0.010 |
Why?
|
Egg Proteins | 1 | 2000 | 23 | 0.010 |
Why?
|
Growth Inhibitors | 1 | 2000 | 27 | 0.010 |
Why?
|
Half-Life | 1 | 2000 | 70 | 0.010 |
Why?
|
Streptococcus pneumoniae | 1 | 2001 | 59 | 0.010 |
Why?
|
Genes, p53 | 1 | 2000 | 53 | 0.010 |
Why?
|
Pongo pygmaeus | 1 | 2000 | 1 | 0.010 |
Why?
|
Hepatitis Antibodies | 1 | 2000 | 5 | 0.010 |
Why?
|
Staphylococcus aureus | 1 | 2001 | 158 | 0.010 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2000 | 108 | 0.010 |
Why?
|
Protein Transport | 1 | 2001 | 394 | 0.010 |
Why?
|
Toll-Like Receptor 4 | 1 | 2001 | 348 | 0.010 |
Why?
|
Aotidae | 1 | 1999 | 9 | 0.010 |
Why?
|
Respiratory Tract Diseases | 1 | 1999 | 35 | 0.010 |
Why?
|
Peptide Biosynthesis | 1 | 1999 | 10 | 0.010 |
Why?
|
Fluorescent Antibody Technique, Indirect | 1 | 1999 | 36 | 0.010 |
Why?
|
Cell Membrane | 1 | 2002 | 490 | 0.010 |
Why?
|
Stress, Physiological | 1 | 2001 | 186 | 0.010 |
Why?
|
Cholera Toxin | 1 | 1999 | 7 | 0.010 |
Why?
|
Stem Cells | 1 | 2001 | 257 | 0.010 |
Why?
|
Hot Temperature | 1 | 1999 | 126 | 0.010 |
Why?
|
Survival Rate | 1 | 2001 | 790 | 0.010 |
Why?
|
Immunoglobulin Idiotypes | 1 | 1998 | 5 | 0.010 |
Why?
|
Macromolecular Substances | 1 | 1999 | 160 | 0.010 |
Why?
|
Langerhans Cells | 1 | 1998 | 11 | 0.010 |
Why?
|
H-2 Antigens | 1 | 1998 | 60 | 0.010 |
Why?
|
Bacterial Toxins | 1 | 1999 | 60 | 0.010 |
Why?
|
Cycloheximide | 1 | 1998 | 21 | 0.010 |
Why?
|
Epidermis | 1 | 1998 | 37 | 0.010 |
Why?
|
Saccharomyces cerevisiae | 1 | 2003 | 530 | 0.010 |
Why?
|
Alum Compounds | 1 | 1998 | 3 | 0.010 |
Why?
|
Secretory Rate | 1 | 1997 | 8 | 0.010 |
Why?
|
Immunoglobulin Isotypes | 1 | 1997 | 24 | 0.010 |
Why?
|
Antibody Specificity | 1 | 1997 | 99 | 0.010 |
Why?
|
Chickens | 1 | 1997 | 91 | 0.010 |
Why?
|
Proteins | 1 | 2003 | 740 | 0.010 |
Why?
|
Immunoglobulin Class Switching | 1 | 1998 | 79 | 0.010 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 1997 | 83 | 0.010 |
Why?
|
Interleukin-2 | 1 | 1997 | 164 | 0.010 |
Why?
|
Mitogens | 1 | 1995 | 10 | 0.010 |
Why?
|
Polyribonucleotides | 1 | 1994 | 2 | 0.010 |
Why?
|
Nucleic Acid Denaturation | 1 | 1994 | 7 | 0.010 |
Why?
|
Ribonuclease H | 1 | 1994 | 18 | 0.010 |
Why?
|
Single-Strand Specific DNA and RNA Endonucleases | 1 | 1994 | 5 | 0.010 |
Why?
|
Blood | 1 | 1994 | 27 | 0.010 |
Why?
|
Nucleic Acid Heteroduplexes | 1 | 1994 | 14 | 0.010 |
Why?
|
Cross Reactions | 1 | 1995 | 123 | 0.010 |
Why?
|
Mycobacterium tuberculosis | 1 | 1999 | 383 | 0.010 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 1994 | 293 | 0.010 |
Why?
|
Receptors, Interleukin-4 | 1 | 1993 | 6 | 0.010 |
Why?
|
Thy-1 Antigens | 1 | 1993 | 21 | 0.010 |
Why?
|
Receptors, Mitogen | 1 | 1993 | 6 | 0.010 |
Why?
|
Cell Aggregation | 1 | 1993 | 21 | 0.010 |
Why?
|
Leukemia, Experimental | 1 | 1992 | 19 | 0.010 |
Why?
|
Lupus Nephritis | 1 | 1992 | 33 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 1996 | 1548 | 0.010 |
Why?
|
Repetitive Sequences, Nucleic Acid | 1 | 1989 | 75 | 0.000 |
Why?
|